Thursday, July 9, 2026
🇺🇸 FDA

Drug profile · INN

abacavir sulfate

ABACAVIR SULFATE

abacavir sulfate (ABACAVIR SULFATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 7
News articles 0
Drug details — abacavir sulfate
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
7
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

abacavir sulfate (ABACAVIR SULFATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN abacavir sulfate
Brand ABACAVIR SULFATE
Mechanism Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Target Human immunodeficiency virus type 1 reverse transcriptase
Route ORAL
Formulation SOLUTION
Originator Teva Pharma GmbH

Mechanism of action

Human immunodeficiency virus type 1 reverse transcriptase inhibitor

Primary target: Human immunodeficiency virus type 1 reverse transcriptase

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. D3 (Penta 21) Phase 3 · Telethon Foundation · HIV-infected
  2. ISIS-APO(a)Rx Phase 2 · IONIS PHARMACEUTICALS · Elevated Lipoprotein(a)
  3. IONIS-APO(a)-LRx Phase 1 · IONIS PHARMACEUTICALS · Elevated Lipoprotein(a)
  4. PRX-P4-003, (-)-FCF Phase 1 · Praxis Precision Medicines · Healthy Volunteers
  5. REGN15160 (IV) Phase 1 · Regeneron UK · Healthy
  6. REGN7508 (IV) Phase 1 · Regeneron UK · Healthy Volunteer
  7. 103900 Approved · Disc Medicine · HIV-infected

Related & competitor drugs

Browse all drugs
  1. efavirenz Antiinfectives for systemic use (J05)
  2. emtricitabine Antiinfectives for systemic use (J05)
  3. etravirine Antiinfectives for systemic use (J05)
  4. nevirapine Antiinfectives for systemic use (J05)
  5. tenofovir alafenamide Antiinfectives for systemic use (J05)
  6. tenofovir disoproxil fumarate Human immunodeficiency virus type 1 reverse transcriptase inhibitor

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. US 12139528

    Treating refractory migraine

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12091388

    Solid state forms of Reproxalap

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. KR 20240034693

    이량체 조영제의 제조

    Expires Wed Mar 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11826322

    Pre-filled syringe

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. KR 20230116805

    가도테리돌 제조를 위한 제조 방법

    Expires Thu Jul 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. KR 20230088753

    파킨슨병 치료를 위한 오피카폰 및 레보도파

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. KR 20230047080

    오피카폰의 고체 분산물

    Expires Wed Apr 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11578338

    Hemipteran active insecticidal protein

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. CY 2022006

    ΠΡΟΦΑΡΜΑΚΑ ΦΟΥΜΑΡΙΚΩΝ ΑΛΑΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΑΓΩΓΗ ΠΟΙΚΙΛΩΝ ΝΟΣΩΝ

    Expires Wed Dec 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11319356

    Interferon alpha 2B variants

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11297838

    Pesticidal compositions and methods

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11028160

    Treating refractory migraine

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11028161

    Treating refractory migraine

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10835503

    Pre-filled syringe

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10544199

    Interferon alpha 2B variants

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10392434

    Treating refractory migraine

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10342867

    Adjuvants

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10323085

    Methods of treating fibromyalgia

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9346746

    R(+)-N-formyl-propargyl-aminoindan

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9339469

    R(+)-N-methyl-propargyl-aminoindan

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is abacavir sulfate?

abacavir sulfate (ABACAVIR SULFATE) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for abacavir sulfate?

ABACAVIR SULFATE is a marketed brand name for abacavir sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of abacavir sulfate?

abacavir sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.